Bactiguard Holding AB (publ) today announces the Nomination Committee’s proposal of Dr. Richard (Rick) Kuntz as new board member. Rick Kuntz brings vast experience from the global medtech industry and has unparalleled knowledge of medical science and technology, clinical research, as well as health policy and medical affairs.
Rick Kuntz comes most recently from listed Medtronic PLC (NYSE:MDT) where he was Chief Medical Officer & Scientific Officer and a member of the Executive Committee. Prior to that, he was the founder and Chief Scientific Officer of the Harvard Clinical Research Institute in Boston. He also served as an Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Clinical Biometrics, and as an Interventional Cardiologist in the division of cardiovascular diseases at the Brigham and Women’s Hospital in Boston. In addition, he served as a founding Governor of the Patient Centered Outcomes Research Institute (PCORI), as part of the US Affordable Care Act. He also served as an advisor to multiple national and regional committees, in the National Academy of Medicine and NIH. He is presently serving as a working group member of NIH’s Helping to End Addiction Long-term® (HEAL) program.
Rick Kuntz received his medical degree from Case Western Reserve University School of Medicine. He completed his residency and chief residency in internal medicine at the University of Texas Southwestern Medical School, Parkland Hospital, Dallas, and then completed fellowships in cardiovascular diseases and interventional cardiology at Harvard Medical School and the Beth Israel Hospital, Boston. He earned his Master of Science degree in Biostatistics from the Harvard T.H. Chan School of Public Health.
Thomas von Koch, Chairman of Bactiguard Holding AB said “Rick Kuntz’s broad and deep knowledge and expertise from the medtech industry, and the scientific and healthcare arena will add huge value to Bactiguard. He has dedicated his entire career to enhancing healthcare and is a thought leader in the conversation around the digital health revolution. As we are in the middle of a transformation journey, Rick’s network, innovative mind and global perspectives will be vital.”
The Nomination Committee for the Annual Shareholders’ meeting 2023 in Bactiguard Holding AB (publ) comprise of Helena Borglund (appointed by TomBact AB), Christian Kinch (appointed by GIDL Invest AB), Jan Ståhlberg (appointed by Jan Ståhlberg), Mats J Andersson (appointed by Nordea Fonder) and Jannis Kitsakis (appointed by Fjärde AP Fonden).
The Nomination Committee’s complete proposals to Bactiguard Holding AB’s Annual Shareholders’ Meeting are included in the notice and the Nomination Committee’s motivation, published on Bactiguard’s website. Bactiguard Holding AB’s Annual Shareholders’ Meeting will be held on Friday May 5, 2023, at 15.00 at the company premises in Tullinge.
For more information, please contact:
Carin Jakobson, CFO, mobile: +46 709 651 665
Bactiguard press office +46 8 440 58 80 email@example.com